Pfizer has agreed to roll back a round of price increases from July 1 that affected more than 100 medicines after President Donald Trump called the company’s CEO and had an “extensive discussion,” the company announced Tuesday.

Now, Pfizer says it will return the drugs to their pre-July 1 list prices “as soon as technically possible,” and it will leave them there until either the President puts in place new healthcare policy or until the end of the year—whichever comes first.

The idea is to “give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access for patients,” Pfizer said in its announcement.

Last week, the Financial Times broke the news that Pfizer was continuing with biannual, incremental list price hikes—generally just under 10 percent—on many of its best-selling drugs, including the erectile dysfunction drug Viagra and Lyrica pain capsules. Such stepwise price increases were common until the escalating cost of drugs sparked fiery backlash from the public and lawmakers. Many of Pfizer’s competitors—though not all—scaled back such increases, saying instead that they would only nudge prices upward once a year and keep individual drug’s price increases under 10 percent per year.

At a bill-signing ceremony on May 30, President Trump claimed that drug companies would go further, saying that they would announce “voluntary massive drops in prices,” within two weeks. But no such announcements from drug companies materialized, and some, including drug-giant Pfizer, appeared to carry on as usual.

On Monday, following the news of Pfizer’s July 1 hikes, the president tweeted that Pfizer and other drug companies “should be ashamed” and that they are “merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere.” He ended his tweet by pledging, “We will respond!”

By Tuesday, Trump tweeted that he had talked with Pfizer’s Chairman and CEO Ian Read, as well as Health and Human Services Secretary Alex Azar. “Pfizer is rolling back price hikes, so American patients don’t pay more,” he tweeted. “We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!”

Americans do not often pay the list price of drugs. Instead, drug makers, insurance providers, and pharmaceutical benefit managers negotiate coverage and behind-the-scenes rebates based on those list prices. Though the delay by Pfizer may not hit patients' pockets directly, critics argue that the point is moot. Larger list prices still contribute to larger overall healthcare costs, which may indirectly lead to higher premiums, for instance.

In May, Trump unveiled a “blueprint” to lower drug prices, which included a variety of regulatory and legislative ideas to reduce costs. Some of those would require Congressional action, which has spurred doubt that the proposals could be debated and implemented within the six-month timeline of Pfizer’s price delay.

Meanwhile, Pfizer is not the only drug maker implementing list price increases on their drugs. Teva Pharmaceuticals, Bayer, Acella Pharmaceuticals, Acorda Therapeutics, and Intercept have also recently introduced price hikes.